Strategikon Pharma
PrivateLast Round
Debt
Jun 10, 2025
Total Funding Raised
$7.03M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Strategikon Pharma operates in Enterprise Software and is based in San Francisco, California. Its latest recorded funding round was a Debt round in June 2025.
Strategikon Pharma is a software company that provides a cloud-based platform, Clinical Maestro, for clinical trial budgeting, sourcing, and outsourcing management.
Sector
Enterprise Software
Verticals
Clinical Trials, Vertical SaaS, Workflow Automation, Compliance & Risk
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Strategikon Pharma Comparables
Compare Strategikon Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Auxilius | 86% | |
| Ledger Run | 86% | |
| ClinAI | 84% |
For institutional investors. Book with your work email.
Strategikon Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jun 10, 2025 | ||||
| Series A Extension | Feb 6, 2024 | ||||
| Grant | Apr 13, 2023 | ||||
| Series A | Apr 22, 2021 | ||||
| Seed | Jan 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Strategikon Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saratoga Ventures | Seed |
| Osage Venture Partners | Series A, Series A Extension |
| Decathlon Capital Partners | Debt |
| Bascom Ventures | Series A |
| Wing Venture Capital | Series A |
| Arizona Commerce Authority | Grant |
| TCA Venture Group | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 102% MoM.
- Aug 27, 2025
Launched Clinical Maestro 5.0, an upgrade to its trial management solution.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 28, 2026
Clinical Maestro attends OCT Nordics 2026 in Denmark in Oct '26, where its founder and chief executive, Anca Copaescu, outlines how clinical-trial data helps detect risks earlier.
- launchesOct 20, 2026
Clinical Maestro launches Source Plus, an intelligence layer that helps pharmaceutical and biotechnology organizations manage complex clinical sourcing, in Massachusetts on Sep 10th '26.
- launchesOct 20, 2026
Clinical Maestro launches VISION Plus, an AI-native intelligence platform release that automates KPIs, performance management and vendor oversight for pharmaceutical business operations, in California on Oct 20th '26.
For institutional investors. Book with your work email.
Strategikon Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Strategikon Pharma's valuation, stock price, and market status.
Is Strategikon Pharma a public or private company?
Strategikon Pharma is a private company.
What is the current stock price of Strategikon Pharma?
Strategikon Pharma is a private company, so its shares have no public market price. Caplight tracks Strategikon Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Strategikon Pharma worth (valuation)?
Valuation information for Strategikon Pharma is not publicly available.
Can I buy Strategikon Pharma stock?
Strategikon Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Strategikon Pharma's last funding round?
Strategikon Pharma's most recent funding round was Debt on June 10, 2025.
Who are the main investors in Strategikon Pharma?
Key investors in Strategikon Pharma include Osage Venture Partners, Decathlon Capital Partners.
Will Strategikon Pharma IPO soon?
No public IPO plans have been announced for Strategikon Pharma.
How can I track Strategikon Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Strategikon Pharma's shares on secondary markets.